Next Century Growth Investors LLC Sells 60,698 Shares of GeneDx Holdings Corp. $WGS

Next Century Growth Investors LLC decreased its holdings in GeneDx Holdings Corp. (NASDAQ:WGS) by 25.9% in the fourth quarter, Holdings Channel reports. The fund owned 173,411 shares of the company’s stock after selling 60,698 shares during the quarter. GeneDx makes up 1.6% of Next Century Growth Investors LLC’s holdings, making the stock its 17th biggest holding. Next Century Growth Investors LLC’s holdings in GeneDx were worth $22,554,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Entropy Technologies LP bought a new position in shares of GeneDx in the 4th quarter valued at about $832,000. Kestra Advisory Services LLC bought a new position in shares of GeneDx in the 4th quarter valued at about $27,000. Prosight Management LP bought a new position in shares of GeneDx in the 4th quarter valued at about $7,153,000. The Manufacturers Life Insurance Company lifted its holdings in shares of GeneDx by 13.2% in the 4th quarter. The Manufacturers Life Insurance Company now owns 24,873 shares of the company’s stock valued at $3,208,000 after acquiring an additional 2,903 shares during the last quarter. Finally, Formula Growth Ltd. bought a new position in shares of GeneDx in the 4th quarter valued at about $1,520,000. Institutional investors own 61.72% of the company’s stock.

Wall Street Analysts Forecast Growth

WGS has been the subject of a number of analyst reports. BTIG Research lowered their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a report on Tuesday, May 5th. Canaccord Genuity Group set a $75.00 price target on shares of GeneDx and gave the company a “buy” rating in a report on Tuesday, May 5th. Zacks Research downgraded shares of GeneDx from a “strong-buy” rating to a “hold” rating in a report on Friday, April 24th. Jefferies Financial Group set a $150.00 price objective on shares of GeneDx in a research note on Monday, February 23rd. Finally, Craig Hallum reissued a “buy” rating and issued a $85.00 price objective on shares of GeneDx in a research note on Tuesday, May 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, GeneDx currently has a consensus rating of “Moderate Buy” and an average price target of $96.43.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Positive Sentiment: Hedge fund manager Eli Casdin is reportedly adding to his GeneDx position, which may be seen as a sign that some sophisticated investors still view the stock as undervalued. Hedge Funder Eli Casdin Is Loading up on GeneDx Shares
• Neutral Sentiment: Several law firms continue to remind investors about the pending securities class action and the August 3 lead-plaintiff deadline. These notices keep the lawsuit in focus, but do not add new operational developments. Investor Alert: Pomerantz Law Firm Reminds Investors…
• Neutral Sentiment: Additional legal updates from Rosen, Faruqi & Faruqi, Schall, Robbins, and others reinforce the litigation backdrop tied to GeneDx’s Fabric Genomics acquisition and the Q1 2026 selloff. ROSEN, TOP RANKED INVESTOR COUNSEL…
• Negative Sentiment: GeneDx CEO Katherine Stueland and CFO Kevin Feeley both sold shares this week. The company says the sales were for tax withholding tied to vesting equity awards, but insider selling can still weigh on sentiment. CEO Form 4 Filing
• Negative Sentiment: The biggest overhang remains the securities class action alleging GeneDx misled investors about reimbursement rates, margin pressure, and the impact of the Fabric Genomics acquisition after a major stock drop and write-off tied to the deal. GeneDx Holdings (WGS) Faces Securities Class Action…

Insider Activity

In related news, Director Keith A. Meister bought 46,273 shares of GeneDx stock in a transaction dated Friday, May 15th. The shares were acquired at an average cost of $38.91 per share, with a total value of $1,800,482.43. Following the completion of the transaction, the director owned 4,784,570 shares in the company, valued at $186,167,618.70. The trade was a 0.98% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Katherine Stueland sold 3,639 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $53.77, for a total transaction of $195,669.03. Following the transaction, the chief executive officer directly owned 96,123 shares in the company, valued at approximately $5,168,533.71. This trade represents a 3.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders acquired 2,256,420 shares of company stock worth $93,144,340 and sold 77,287 shares worth $5,153,215. Insiders own 29.60% of the company’s stock.

GeneDx Stock Down 1.8%

Shares of NASDAQ WGS opened at $59.92 on Friday. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The company has a market cap of $1.78 billion, a P/E ratio of -22.36 and a beta of 1.96. GeneDx Holdings Corp. has a 1 year low of $32.21 and a 1 year high of $170.87. The firm has a 50-day simple moving average of $54.95 and a two-hundred day simple moving average of $90.19.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.22). The firm had revenue of $102.25 million during the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.During the same period in the previous year, the business earned ($0.23) EPS. Research analysts anticipate that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

GeneDx Company Profile

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.